High frequency of BRAF V600E mutation in Iranian population ameloblastomas.
| Autor: | Derakhshan S; North Kargar St., School of Dentistry Tehran University of Medical Sciences Tehran, Iran. Postal Code: 1439955991 Memarhaamirreza@yahoo.com., Aminishakib P, Karimi A, Saffar H, Abdollahi A, Mohammadpour H, Kharazi Fard MJ, Memarha A |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Medicina oral, patologia oral y cirugia bucal [Med Oral Patol Oral Cir Bucal] 2020 Jul 01; Vol. 25 (4), pp. e502-e507. Date of Electronic Publication: 2020 Jul 01. |
| DOI: | 10.4317/medoral.23519 |
| Abstrakt: | Background: Ameloblastoma is a common locally invasive but slow-growing neoplasm of the jaws with an odontogenic origin. Association between BRAF V600E mutation and clinicopathologic features and behavior of ameloblastoma remains controversial. This study aimed to evaluate BRAF V600E gene mutation and expression of its related proteins with clinicopathologic parameters in conventional ameloblastoma. Material and Methods: 50 Formalin-fixed paraffin-embedded blocks were included in this study. Immunohistochemistry was done using rabbit monoclonal BRAF V600E mutation-specific antibody VE1. Quantitative real-time polymerase chain reaction assay was used for evaluating of BRAF V600E mutation. Results: Expression of BRAF V600E antibody was Positive in 42 out of 50 cases (84%). 46 (92%) out of 50 specimens showed BRAF V600E mutation. There were 13 cases of recurrence (26%). 3 out of 4 cases with negative mutations did not show recurrence. Conclusions: We report the highest frequency (92%) of BRAF V600E mutation in ameloblastomas in the Iranian population. Although there was not a significant association between BRAF V600E‑positive immunoexpression and recurrence and clinicopathologic parameters, its high frequency could emphasize its role as a therapeutic marker in the future. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|